Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
Status:
Completed
Trial end date:
2012-11-05
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine
732462 can lead to a reduction in viral load, and impact on the course of human
immunodeficiency virus type 1 (HIV-1) infection. In HIV-1 infected persons who have not yet
started antiretroviral therapy (ART), such a vaccine would potentially lead to a delay in the
initiation of treatment.